| 13.7 -0.1 (-0.72%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 16.73 | 1-year : | 19.55 |
| Resists | First : | 14.33 | Second : | 16.73 |
| Pivot price | 13.73 |
|||
| Supports | First : | 13.23  |
Second : | 12.56 |
| MAs | MA(5) : | 13.66 |
MA(20) : | 13.74 |
| MA(100) : | 13.38 |
MA(250) : | 12.36 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 62.3 |
D(3) : | 51.1 |
| RSI | RSI(14): 53.1 |
|||
| 52-week | High : | 17.14 | Low : | 8.48 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ BNTC ] has closed above bottom band by 46.1%. Bollinger Bands are 63.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 13.98 - 14.06 | 14.06 - 14.13 |
| Low: | 13.09 - 13.19 | 13.19 - 13.27 |
| Close: | 13.56 - 13.72 | 13.72 - 13.83 |
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
Sat, 27 Sep 2025
Benitec Biopharma (NASDAQ:BNTC) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Thu, 25 Sep 2025
Benitec Biopharma (NASDAQ:BNTC) Releases Quarterly Earnings Results, Misses Estimates By $0.18 EPS - MarketBeat
Wed, 24 Sep 2025
BNTC Analyst Rating: JMP Securities Reiterates Market Outperform - GuruFocus
Wed, 24 Sep 2025
Benitec Biopharma Inc reports results for the quarter ended June 30 - Earnings Summary - TradingView
Mon, 22 Sep 2025
Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update - GlobeNewswire
Mon, 22 Sep 2025
Benitec Biopharma Inc expected to post a loss of 29 cents a share - Earnings Preview - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 26 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 3.1 (%) |
| Held by Institutions | 91 (%) |
| Shares Short | 1,330 (K) |
| Shares Short P.Month | 1,430 (K) |
| EPS | -5.04 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.81 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -31.4 % |
| Return on Equity (ttm) | -48.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.15 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -19 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -2.73 |
| PEG Ratio | 0 |
| Price to Book value | 3.58 |
| Price to Sales | 0 |
| Price to Cash Flow | -19.27 |
| Dividend | 0.75 |
| Forward Dividend | 0 |
| Dividend Yield | 5.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|